Press Releases

2019

ANCHIANO THERAPEUTICS ENTERS INTO AN EXCLUSIVE OPTION TO LICENSE AGREEMENT FOR NOVEL PAN-RAS INHIBITOR AND PDE10/β-catenin INHIBITOR PROGRAMS| September 23

ANCHIANO THERAPEUTICS TO PRESENT AT THE LADENBURG THALMANN HEALTHCARE CONFERENCE| September 20

ANCHIANO THERAPEUTICS TO PRESENT AT THE BAIRD 2019 GLOBAL HEALTHCARE CONFERENCE | September 3

ANCHIANO THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS | August 5

ANCHIANO THERAPEUTICS DELISTS ORDINARY SHARES FROM THE TEL AVIV STOCK EXCHANGE | June 19

ANCHIANO THERAPEUTICS ANNOUNCES APPOINTMENT OF SALAR ROSHAN AS HEAD OF BUSINESS DEVELOPMENT | May 29

ANCHIANO THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS | May 22

ANCHIANO THERAPEUTICS TO PRESENT AT THE OPPENHEIMER 29TH ANNUAL HEALTHCARE CONFERENCE | March 14

ANCHIANO THERAPEUTICS INITIATES PROCESS TO VOLUNTARILY DELIST ITS ORDINARY SHARES FROM THE TEL AVIV STOCK EXCHANGE | March 14

ANCHIANO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS | March 12

ANCHIANO THERAPEUTICS ANNOUNCES CLOSING OF $30.5 MILLION INITIAL PUBLIC OFFERINGFebruary 14

ANCHIANO THERAPEUTICS ANNOUNCES PRICING OF $30.5 MILLION INITIAL PUBLIC OFFERINGFebruary 12

ANCHIANO THERAPEUTICS ANNOUNCES FILING OF F-1 REGISTRATION STATEMENT FOR U.S. INITIAL PUBLIC OFFERING | January 7

 

2018

ANCHIANO THERAPEUTICS ANNOUNCES INITIATION OF ITS PIVOTAL CODEX STUDY OF INODIFTAGENE VIXTEPLASMID IN PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER | December 18

ANCHIANO THERAPEUTICS ANNOUNCES APPOINTMENT OF DR. DAVID KERSTEIN AS NEW CHIEF MEDICAL OFFICER| November 26

ANCHIANO THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL AND OPERATIONAL RESULTS | November 19

ANCHIANO THERAPEUTICS APPOINTS DR. STEPHEN HOFFMAN AND ROBERT CONNELLY TO ITS BOARD OF DIRECTORS | November 12

ANCHIANO THERAPEUTICS ANNOUNCES CONFIDENTIAL SUBMISSION OF DRAFT REGISTRATION STATEMENT FOR U.S. INITIAL PUBLIC OFFERING |  October 31

ANCHIANO THERAPEUTICS TO PRESENT AT H.C. WAINWRIGHT 20th ANNUAL GLOBAL INVESTMENT CONFERENCE| September 5

ANCHIANO THERAPEUTICS APPOINTS EFRAT MAKOV TO BOARD OF DIRECTORS| August 30

BIOCANCELL ANNOUNCES COMPANY NAME CHANGE TO ANCHIANO THERAPEUTICS | August 27

BIOCANCELL ANNOUNCES SECOND QUARTER FINANCIAL AND OPERATIONAL RESULTS | August 22

BIOCANCELL ANNOUNCES COMPLETION OF $23 MILLION PIPE FINANCING | July 3

NOTICE OF THE CONVENING OF AN EXTRAORDINARY GENERAL MEETING OF THE COMPANY’S SHAREHOLDERS | July 1

BIOCANCELL ANNOUNCES FIRST QUARTER 2018 FINANCIAL AND OPERATIONAL RESULTS AND PROVIDES CORPORATE UPDATE | May 15

NOTICE OF THE CONVENING OF AN ANNUAL AND EXTRAORDINARY GENERAL MEETING OF THE COMPANY’S SHAREHOLDERS | April 26

BIOCANCELL ANNOUNCES $23 MILLION PIPE FINANCING| April 13

BIOCANCELL ANNOUNCES TWO NEW KEY HIRES IN CLINICAL DEVELOPMENT AND CLINICAL OPERATIONS | March 7

BIOCANCELL PRESENTS FINAL DATA FROM ITS PHASE 2 STUDY OF BC-819 FOR EARLY STAGE BLADDER CANCER AT THE 2018 ASCO GENITOURINARY CANCERS SYMPOSIUM | February 9

BIOCANCELL ANNOUNCES TERMS OF $25 MILLION FUNDRAISING ROUND | January 23

 

2017

SHAREHOLDERS TURN DOWN TENDER OFFER TO TAKE BIOCANCELL PRIVATE | December 28

INVESTORS INITIATE TENDER OFFER TO TAKE BIOCANCELL PRIVATE AHEAD OF PLANNED FUNDRAISING ROUND | December 11

BIOCANCELL ANNOUNCES UPDATED RESULTS FROM THE PHASE 2 CLINICAL TRIAL OF BC-819 AND BCG IN PATIENTS WITH BLADDER CANCER | November 15

BIOCANCELL ANNOUNCES EXPLORATION OF FUNDING ROUND CONDITIONED ON A GOING PRIVATE TRANSACTION | October 30

BIOCANCELL ANNOUNCES APPOINTMENT OF MS. RUTI ALON TO BOARD OF DIRECTORS | August 14

NOTICE OF THE CONVENING OF AN EXTRAORDINARY GENERAL MEETING OF THE COMPANY’S SHAREHOLDERS | August 1

 

2015

BIOCANCELL ADVANCES INTELLECTUAL PROPERTY PORTFOLIO IN THE U.S. | November 5

BIOCANCELL ADVANCES PHASE III CLINICAL PROGRAM FOR BLADDER CANCER | October 1

BIOCANCELL RECEIVES FDA FAST TRACK DESIGNATION FOR BC-819 FOR TREATMENT OF BLADDER CANCER PATIENTS | September 10

BIOCANCELL ANNOUNCES DEVELOPMENT OF NEW DIAGNOSTIC PRODUCT BC-830 | June 21

BIOCANCELL FILES INTERNATIONAL PATENT REQUEST FOR NEW DRUG FORMULATION | May 6

 

2014

BIOCANCELL RECEIVES OUTLINE FOR APPROVAL FOR TWO PHASE III BLADDER CANCER TRIALS | October 29

BIOCANCELL ANNOUNCES RESULTS OF BLADDER CANCER TRIAL | September 23

 

2013

BIOCANCELL ANNOUNCES FINAL PHASE IIB BLADDER CANCER TRIAL RESULTS | March 17

BIOCANCELL ANNOUNCES FIRST-STAGE PHASE IIB PANCREATIC CANCER TRIAL RESULTS | February 4

 

2012

BIOCANCELL ANNOUNCES PHASE I/IIA OVARIAN CANCER TRIAL RESULTS (update)| May 8

BIOCANCELL ANNOUNCES PHASE I/IIA OVARIAN CANCER TRIAL RESULTS | March 13

 

2011

BIOCANCELL RECEIVES FDA FAST TRACK DESIGNATION | October 4

BIOCANCELL TO COMMENCE PHASE IIB PANCREATIC CANCER CLINICAL TRIAL | July 21

 

2010

BIOCANCELL ANNOUNCES PHASE I/IIA PANCREATIC CANTER TRIAL RESULTS | December 27

BIOCANCELL RECEIVES ORPHAN DRUG APPROVAL FOR PANCREATIC CANCER TREATMENT | August 15

 

2009

BIOCANCELL COMMENCES PHASE I/IIA PANCREATIC CANCER TRIAL | November 29

BIOCANCELL USED BC-919 TO TREAT MICE WITH LUNG CANCER | August 13

BIOCANCELL COMPLETES $3.65 MILLION FUNDRAISING ROUND | August 3

 

2008

BIOCANCELL REVEALS PRE-CLINICAL RESULTS IN PANCREATIC CANCER TREATMENT | April 7

 

2007

BIOCANCELL ANNOUNCES PRE-CLINICAL DRUG EFFECTIVENESS IN OVARIAN CANCER AND LIVER METASTASES | October 23

BIOCANCELL ANNOUNCES SUCCESSFUL RESULTS IN CLINICAL TRIAL | September 24